Table 2.
Characteristics of therapy in a/m STS patients (pts) in dependence of sarcopenia
| Variables | All pts | Non-sarcopenic pts | Sarcopenic pts | P |
|---|---|---|---|---|
| n = 89 (100%) | n = 61 (%) | n = 28 (%) | ||
| Number of administered CTx, median (range) | 2 (1–8) | 2 (1–8) | 1.5 (1–7) | 0.112 |
| Number of administered Sx, median (range) | 0 (0–7) | 0 (0–7) | 0 (0–4) | 0.733 |
| Number of administered RTx, median (range) | 0 (0–4) | 0 (0–3) | 0 (0–4) | 0.482 |
| Cumulative no. of therapies, median (range) | 4 (1–11) | 4 (1–11) | 2.5 (1–11) | 0.132 |
| MT – (CTx only), n (%) | 37 (41.6) | 22 (36.1) | 15 (53.6) | 0.122 |
| MT + (CTx + Sx/RTx), n (%) | 52 (58.4) | 39 (63.9) | 13 (46.4) | |
| Medical treatment | ||||
| Doxorubicin, n (%) | 34 (38.2) | 25 (41.0) | 9 (21.4) | |
| Doxorubicin + Ifosfamide, n (%) | 26 (29.2) | 20 (32.8) | 6 (21.4) | |
| Other, n (%) | 29 (32.6) | 16 (26.2) | 13 (46.4) | |
| Clinical response (CTx 1) | 0.089 | |||
| CR, n (%) | 1 (1.1) | 0 | 1 (3.6) | |
| PR, n (%) | 20 (22.5) | 17 (27.9) | 3 (10.7) | |
| SD, n (%) | 16 (18.0) | 13 (21.3) | 3 (10.7) | |
| PD, n (%) | 40 (44.9) | 24 (39.3) | 16 (57.1) | |
| NE, n (%) | 12 (13.5) | 7 (11.5) | 5 (17.9) | |
| ORR, n (%) | 21 (23.6) | 17 (27.9) | 4 (14.3) | 0.161 |
| DCR, n (%) | 37 (41.6) | 30 (49.2) | 7 (25) | 0.032 |
| Treatment discontinued, n (%) | 58 (65.2) | 40 (65.6) | 18 (64.4) | 0.906 |
| Reason for discontinuation of CTx | 0.849 | |||
| Progression n (%) | 42 (75.0) | 29 (76.3) | 13 (72.2) | |
| Toxicity, n (%) | 12 (21.4) | 8 (21.1) | 4 (22.2) | |
| Other, n (%) | 2 (3.6) | 1 (2.6) | 1 (5.6) | |
CTx chemotherapy, Sx surgery, RTx Radiotherapy, Cumulative number of therapies: Sum of administered CTx, Sx and RTx, MT multimodal therapy, CR complete response, SD stable disease, PR partial response, Mixed: mixed response, PD progressive disease, ORR objective response rate (CR + PR), DCR Disease control rate (CR + PR + SD)